Prurigo Nodularis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Celldex Therapeutics, Incyte Corporation, Genentech, Trevi Therapeutics, Chugai Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Prurigo Nodularis pipeline constitutes 5+ key companies continuously working towards developing 5+ Prurigo Nodularis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Prurigo Nodularis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Prurigo Nodularis Market.

The Prurigo Nodularis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Prurigo Nodularis Pipeline Report: https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Prurigo Nodularis treatment therapies with a considerable amount of success over the years.
• Prurigo Nodularis companies working in the treatment market are Celldex Therapeutics, Incyte Corporation, Genentech, Trevi Therapeutics, Chugai Pharmaceutical, and others, are developing therapies for the Prurigo Nodularis treatment
• Emerging Prurigo Nodularis therapies in the different phases of clinical trials are- CDX-0159, INCB054707, Vixarelimab, Haduvio, Nemolizumab, and others are expected to have a significant impact on the Prurigo Nodularis market in the coming years.
• In March 2025, Incyte (Nasdaq: INCY) announced findings from its pivotal Phase 3 TRuE-PN clinical trial program, including the TRuE-PN1 and TRuE-PN2 studies, assessing the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (18 years and older) with prurigo nodularis (PN).
• In March 2025, Incyte (Nasdaq: INCY) announced positive topline results from its pivotal Phase 3 STOP-HS trial assessing the safety and efficacy of povorcitinib (INCB054707), an oral JAK1 inhibitor, in adults (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Povorcitinib, a selective JAK1 inhibitor, is also being investigated in Phase 3 trials for vitiligo and prurigo nodularis (PN) and in Phase 2 trials for asthma and chronic spontaneous urticaria (CSU).
• In February 2025, Galderma (SWX:GALD) announced that the European Commission has granted approval for Nemluvio in the EU to treat both moderate-to-severe atopic dermatitis and prurigo nodularis. Nemluvio is now authorized for subcutaneous use in patients aged 12 and older with moderate-to-severe atopic dermatitis requiring systemic therapy, as well as in adults with moderate-to-severe prurigo nodularis eligible for systemic treatment.
• In November 2024, Galderma announced that the randomized Phase III OLYMPIA 1 trial assessing nemolizumab monotherapy in adults with moderate-to-severe prurigo nodularis (PN) successfully met its primary and all key secondary endpoints. This double-blind, placebo-controlled study evaluated the efficacy and safety of the monoclonal antibody compared to a placebo over a 24-week treatment period. The trial included 286 participants aged 18 years or older with moderate-to-severe Prurigo Nodularis.

Prurigo Nodularis Overview
Prurigo Nodularis is a chronic skin condition characterized by intensely itchy, firm, raised nodules that usually appear on the arms, legs, and trunk. The constant itching leads to scratching, which worsens the lesions and creates a vicious itch-scratch cycle. PN is often associated with underlying conditions like eczema, atopic dermatitis, kidney disease, or liver disorders. It significantly impacts quality of life due to the severe itch and visible skin changes. Treatment typically focuses on controlling the itch, reducing inflammation, and breaking the scratch cycle using topical therapies, systemic medications, and newer biologic treatments.

Get a Free Sample PDF Report to know more about Prurigo Nodularis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Prurigo Nodularis Drugs Under Different Phases of Clinical Development Include:
• CDX-0159: Celldex Therapeutics
• INCB054707: Incyte Corporation
• Vixarelimab: Genentech
• Haduvio: Trevi Therapeutics
• Nemolizumab: Chugai Pharmaceutical

Prurigo Nodularis Pipeline Therapeutics Assessment
• Prurigo Nodularis Assessment by Product Type
• Prurigo Nodularis By Stage and Product Type
• Prurigo Nodularis Assessment by Route of Administration
• Prurigo Nodularis By Stage and Route of Administration
• Prurigo Nodularis Assessment by Molecule Type
• Prurigo Nodularis by Stage and Molecule Type

DelveInsight's Prurigo Nodularis Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Prurigo Nodularis product details are provided in the report. Download the Prurigo Nodularis pipeline report to learn more about the emerging Prurigo Nodularis therapies
https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Prurigo Nodularis Therapeutics Market include:
Key companies developing therapies for Prurigo Nodularis are - Sanofi, Maruho, Menlo Therapeutics, Trevi Therapeutics, Galderma, Sanofi/Regeneron, Kiniksa Pharmaceuticals, Amgen, Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Maruho, and many others.

Prurigo Nodularis Pipeline Analysis:
The Prurigo Nodularis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Prurigo Nodularis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prurigo Nodularis Treatment.
• Prurigo Nodularis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Prurigo Nodularis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prurigo Nodularis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Prurigo Nodularis drugs and therapies
https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Prurigo Nodularis Pipeline Market Drivers
• Increasing prevalence of the disease, development of Novel Therapies to treat Prurigo Nodularis are some of the important factors that are fueling the Prurigo Nodularis Market.

Prurigo Nodularis Pipeline Market Barriers
• However, lack of expenditure in the treatment sector, side-effects associated with the treatment and other factors are creating obstacles in the Prurigo Nodularis Market growth.

Scope of Prurigo Nodularis Pipeline Drug Insight
• Coverage: Global
• Key Prurigo Nodularis Companies: Celldex Therapeutics, Incyte Corporation, Genentech, Trevi Therapeutics, Chugai Pharmaceutical, and others
• Key Prurigo Nodularis Therapies: CDX-0159, INCB054707, Vixarelimab, Haduvio, Nemolizumab, and others
• Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies
• Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers

Request for Sample PDF Report for Prurigo Nodularis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Prurigo Nodularis Report Introduction
2. Prurigo Nodularis Executive Summary
3. Prurigo Nodularis Overview
4. Prurigo Nodularis- Analytical Perspective In-depth Commercial Assessment
5. Prurigo Nodularis Pipeline Therapeutics
6. Prurigo Nodularis Late Stage Products (Phase II/III)
7. Prurigo Nodularis Mid Stage Products (Phase II)
8. Prurigo Nodularis Early Stage Products (Phase I)
9. Prurigo Nodularis Preclinical Stage Products
10. Prurigo Nodularis Therapeutics Assessment
11. Prurigo Nodularis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Prurigo Nodularis Key Companies
14. Prurigo Nodularis Key Products
15. Prurigo Nodularis Unmet Needs
16 . Prurigo Nodularis Market Drivers and Barriers
17. Prurigo Nodularis Future Perspectives and Conclusion
18. Prurigo Nodularis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Prurigo Nodularis Market https://www.delveinsight.com/report-store/prurigo-nodularis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Prurigo Nodularis Epidemiology https://www.delveinsight.com/report-store/prurigo-nodularis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Prurigo Nodularis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.